RHYTHM PHARMACEUTICALS, INC. Amortization of Debt Issuance Costs
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Amortization of Debt Issuance Costs of $46.00 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2022-08-03
- 2022-06-30: Amortization of Debt Issuance Costs 6 month $46.00K.
| Period end | Amortization of Debt Issuance Costs 6 month |
|---|---|
| 2022-06-30 | $46.00K 10-Q · filed 2022-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |